European Biopharmaceutical Review |
 |
|
|
|
|
 |
| |
|
|
Editor’s Letter
Deborah O’Neil reviews how regulations can assist with safer therapies, and explores some of this issue’s focus features.
|
|
|
|
|
Monitoring Aggregation
Characterisation Techniques
Therapeutic protein molecules are prone to degradation in the body if their binding efficacy is lost, but Pauline Carnell and Sarah Newell at NanoSight Ltd suggest that a new technique may provide the solution.
|
|
|
|
Strategy and Finance
Rising Up: Part 2
In the second of a two-part series, Graham Scholefield and Markus Thunecke at Catenion explore new strategies to integrate payer needs with R&D decision-making.
|
|
|
|
Antimicrobial Therapeutics
First Class
Vanessa Duncan, Douglas Fraser-Pitt and Derry Mercer at NovaBiotics Ltd review how peptide anti-infectives are offering a different approach to the therapeutic field.
|
|
|
|
|
NMR-Based Methods
Data Streaming
A new tool for optimising cell feed strategy and upstream process development has been unveiled. Nuclear magnetic resonance technology is successfully improving Quality by Design data, says Frederic Girard at Spinnovation Biologics.
|
|
|
|
Phenotypic Drug Discovery
Target Practice
Target deconvolution using phenotypic screening methods is beginning to provide greater opportunities for the development pipeline. Jim Freeth at Retrogenix explains how this could help to produce many new and innovative drugs.
|
|
|
Drug Discovery
Data Mine
Pooja Jain at PharmaPendium reports on how the amount of data generated by the industry is outweighing the information management strategies that are already in place.
|
|
|
|
Oncology Approvals
Cancer Concerns
Vijaya Vulapalli at GBI Research discusses the many challenges that the oncology sector faces. Inaccessible treatments, high costs and increasing death rates are just a few of the obstacles that need to be tackled.
|
|
|
Cancer Diagnostics
Making a Mark
Alfred Hansel and Martina Schmitz at oncgnostics GmbH explore how DNA methylation-based epigenetic markers are demonstrating their vast diagnostic potential for in vitro testing.
|
|
|
|
Bioprocess Monitoring
Real-Time Approach
The complexity of using living cells as production systems represents a major challenge in bioprocess design and control. Markus Luchner, Timo Schmidberger and Gerald Striedner at ACIB highlight how proton transfer reaction mass spectrometers hold the potential to change this.
|
|
|
|
Bioregional
Investing in the Future
Uldouz Berenjforoush at Frost & Sullivan examines why Azerbaijan is becoming an attractive destination for new investors, as their expanding economy and plans to develop primary care come to the forefront.
|
|
|
|
Industry Interview
Business Speak
Dr Jean-Pierre Wery, President of Crown Bioscience, speaks to EBR to discuss his business philosophy, share his goals for the coming year, and reveal the secret of his success.
|
|
|
|
Molecular Treatments
mRNA: Get the Message
Ingmar Hoerr at CureVac reveals how messenger ribonucleic acids are beginning to transform modern molecular medicine as a novel therapeutic class.
|
|
|
|
Proof of Concept
Adding Value
Pinar Akpinar, Cyril Clarke and Nigel Gregson illustrate how proof-of-concept and proof-of-value are linked when bringing a new drug to market.
|
|
|
In Brief
Return of the Blockbuster?
Against the popular consensus of industry leaders, Emile Bellott considers whether the emphasis on niche indications is over as the blockbuster era makes a comeback.
|
|
|
|
Bio-Security
Pipeline of Terror
Boaz Ganor, Miri Halpern Wernli and Mollie Shields Uehling at Actelion debate the threat of terrorism to the biopharmaceutical industry. What can the industry do to protect itself?
|
|
|
|
Four-Dimensional Imaging
A Deadly Bite
Dr Bülent Peker at Olympus Europa demonstrates how four-dimensional imaging could tackle the complex blood stage of the malarial pathogen Plasmodium falciparum.
|
|
|
Image Processing Techniques
Marked Data
More sophisticated image analysis techniques would allow for greater optimisation of biomarker data. Andrew J Buckler and James C Keith at Elucid Bioimaging Inc explain the advantages that this could bring.
|
|
|
|
|
|
